Ebina Lab/BIKEN Innovative Vaccine Research Alliance Laboratories  Virus Vaccine Group

It is difficult to develop vaccines against pathogens that cannot be suppressed by antibody-mediated immunity alone, pathogens that cannot be cultured, or those whose infection is difficult to evaluate due to the absence of animal models. The Viral Vaccine Project is conducting virus research with the aim of developing here in Japan, the world's first vaccines targeting these infectious diseases.

 

Human parvovirus B19 infection in pregnant women causes hydrops fetalis due to severe fetal anemia. Vaccines against this infection are needed, but have not yet been developed. The limitations of developing a vaccine include the following: a virus culture method has not been established, the virus host is limited to humans, and there is no adequate animal model available. We are developing novel parvovirus vaccines using various approaches, such as analysis of parvovirus replication mechanism and performing human epidemiological research.

 

Viruses that replicate in a variety of organisms, apart from humans, have unique properties that can be applied as vaccines for humans. We are conducting virus research with the aim of creating powerful, safe, and novel vaccine platforms by taking advantage of the characteristics of various viruses. 
 

Staff

  • SA Assoc. Prof.: Hirotaka Ebina

Publications

  • 1) Quantification of a cell-mediated immune response against varicella zoster virus by assessing responder CD4high memory cell proliferation in activated whole blood cultures. Haredy AM., et al. Vaccine (2019) 37(36):5225-5232.
    2) Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Ebina H., et al. Scientific Reports (2013) 3:2510.
    3) Integrase-independent HIV-1 infection is augmented under conditions of DNA damage and produces a viral reservoir. Ebina H., et al. Virology (2012) 427(1):44-50.
    4) Host genome surveillance for retrotransposons by transposon-derived proteins. Cam HP., etal. Nature (2008) 451(7177):431-6.